Skip to main content
. 2016 Dec 10;8(2):3495–3508. doi: 10.18632/oncotarget.13849

Figure 5. VSVΔ51-GFP reduces viability of 76-9 cells in vitro, but does not synergize with LCL161.

Figure 5

A, B. 76-9 RMS cells were treated with vehicle (DMSO) or 5 μM LCL161 and increasing MOI of VSVΔ51-GFP or the non-replicating VSVΔG-GFP. C-E. 76-9 cells were treated with vehicle control (DMSO) or 5 μM LCL161 and innate immune stimuli, including BSA (80 pg/mL), PBS control, VSVΔ51-GFP (MOI 0.1), IFNγ (1000 U/mL), TWEAK (100 ng/mL). mRNA expression of TNFα, interferon regulatory factor 1 (IRF1) and IRF7 was assessed by qRT-PCR. F. Cell culture supernatant from VSVΔ51-GFP-infected (MOI 0.01) 76-9 cells was UV inactivated and applied to naïve 76-9 cells in the presence of DMSO or 5 μM LCL161. G. TNFα concentration in media from 76-9 cells after treatment with PBS or VSVΔ51-GFP (MOI 0.01) was measured by using ELISA.